Breaking News

Cryoport Teams Up with TiGenix

Will provide cold chain logistics for clinical trial of SEPCELL for the treatment of sepsis

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Cryoport, a provider of temperature controlled logistics for the life sciences industry, is partnering with TiGenix as it conducts its SEPCELL phase Ib/IIa clinical study. The study will evaluate the safety and efficacy of expanded Cx611 allogeneic adipose‐derived stem cells (eASCs) for the treatment of sepsis in adult patients with severe community‐acquired bacterial pneumonia and admitted to the intensive care unit. TiGenix is a developer of allogeneic stem cell therapies targeting autoi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters